These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 8611049

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Front-line drug discovery system for cancer].
    Mizukami T.
    Gan To Kagaku Ryoho; 2008 Dec; 35(13):2293-300. PubMed ID: 19098393
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Cancer chemopreventive agents-drugs for the 21st century?
    Baer-Dubowska W.
    Acta Pol Pharm; 2006 Dec; 63(5):369-73. PubMed ID: 17357586
    [Abstract] [Full Text] [Related]

  • 34. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD.
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [Abstract] [Full Text] [Related]

  • 35. [Basic rules and problems of phase study of new anticancer agents].
    Saito T.
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):377-82. PubMed ID: 6703716
    [Abstract] [Full Text] [Related]

  • 36. Targeting oncogenes and tumor suppressors genes to mitigate chemoresistance.
    Fatemian T, Chowdhury EH.
    Curr Cancer Drug Targets; 2014 Mar; 14(7):599-609. PubMed ID: 25308718
    [Abstract] [Full Text] [Related]

  • 37. [Current emphasis in experimental cancer research and its relation to clinical oncology].
    Seeber S.
    Onkologie; 1986 Oct; 9 Suppl 2():14, 17-9. PubMed ID: 3534669
    [No Abstract] [Full Text] [Related]

  • 38. [Main problems of the method of clinical study of new antineoplastic agents].
    Astrakhan VI.
    Vestn Akad Med Nauk SSSR; 1966 Oct; 21(4):85-92. PubMed ID: 4882836
    [No Abstract] [Full Text] [Related]

  • 39. Signalling pathways as targets for anticancer drug development.
    Powis G.
    Pharmacol Ther; 1994 Oct; 62(1-2):57-95. PubMed ID: 7991648
    [Abstract] [Full Text] [Related]

  • 40. [The introduction of new drugs from the basic research to clinical application--issues in the drug development].
    Watanabe T, Saijo N.
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():289-91. PubMed ID: 7986105
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.